• Users Online: 737
  • Print this page
  • Email this page
REVIEW FOR THE SHEIKH HAMDAN BIN RASHID AL MAKTOUM AWARD FOR MEDICAL SCIENCES
Year : 2014  |  Volume : 7  |  Issue : 3  |  Page : 277-287

Imatinib (Glivec®) as a paradigm of targeted cancer therapies


Cancer Institute, Oregon Health & Science University, Portland, OR, USA

Correspondence Address:
Brian J Druker
Cancer Institute, Oregon Health & Science University, Portland, OR
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7707/hmj.343

Rights and Permissions

Imatinib (Glivec®, Novartis Pharmaceuticals UK Ltd, Basel, Switzerland) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of the BCR-ABL tyrosine kinase as a therapeutic target in chronic myeloid leukaemia and the steps for the development of an agent to specifically inactivate this abnormality. The results of unprecedented clinical trials are reviewed alongside a description of resistance mechanisms and the development of novel tyrosine kinase inhibitors to circumvent resistance. As imatinib also inhibits the tyrosine kinase activity of KIT and the platelet-derived growth factor receptors, the extension of imatinib to malignancies driven by these kinases is described. Finally, the application of the paradigm of targeting molecular pathogenetic events to other malignancies is explored.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed219    
    Printed11    
    Emailed0    
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal